Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Summary

To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.

Timeline

Start

2013-01

Primary completion

2014-08

Completion

2014-08

Publications

• Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, Stach C, Zamacona M, Dorner T, Urowitz M, Hiepe F. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis. 2017 Nov;76(11):1837-1844. doi: 10.1136/annrheumdis-2017-211388. Epub 2017 Aug 5.

Drugs

Indications